Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

SIMPLE SUMMARY: REarranged during Transfection (RET) is an emerging target for several types of cancer, including non-small cell lung cancer (NSCLC). The recent U.S. FDA approval of pralsetinib and selpercatinib raises issues regarding the emergence of secondary mutations and amplifications involved...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Fancelli, Sara, Caliman, Enrico, Mazzoni, Francesca, Brugia, Marco, Castiglione, Francesca, Voltolini, Luca, Pillozzi, Serena, Antonuzzo, Lorenzo
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7961559/
https://ncbi.nlm.nih.gov/pubmed/33806299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051091
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky